The money will be used to advance the Syntax platform, DNA Script's first commercial product that is powered by its proprietary enzymatic DNA synthesis technology, the company said. According to DNA Script, Syntax can help scientists rapidly print synthetic nucleic acids for genomics and molecular biology applications. On-demand printing enables labs to iterate without waiting days or weeks to receive genetic material from third-party service providers.

DNA Script is a life sciences technology company developing novel and efficient ways to design and manufacture nucleic acids.

Accounts and funds advised by T. Rowe Price Associates and Baillie Gifford participated in the funding round, along with Healthcor Management, Eurekare, and Irving Investors. They joined Coatue Management, Catalio Capital Management, Fidelity Management and Research Company, Columbia Threadneedle Investments, Casdin Capital plus other investors that participated in the first financing round.